Stem Cell Therapeutics Markets: 2014 Report
DUBLIN, Nov. 17, 2014 Research and Markets has announced the addition of the "Stem Cell Therapeutics Markets" report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells have become effective tools in blood diseases, musculoskeletal diseases, digestive disorders and many other areas.
Stem Cell Therapeutics Markets conducts in-depth research into the stem cell market opportunity by assessing current technology performance, new developments, pricing trends and government positions on the topic. A combination approach - using both a bottom-up model and comparing data with a top-down analysis - was used to determine market size and market forecasts.
Over the next several years, as researchers introduce a growing variety of technologies, products and services based upon stem cells, revenues related to stem cell therapies will increase dramatically. New therapeutic applications of stem cells could potentially be realized in all of the following disease segments:
- Blood and Blood-Forming Organs
- Circulatory System
- Endocrine and Metabolic System and Immunity Disorders
- Eye
- Gastrointestinal System
- Musculoskeletal System and Connective Tissue Disorders
- Neoplasms
- Nervous System
- Respiratory System
- Skin and Subcutaneous Tissues
There are more than 4,000 research projects underway for stem cell therapies throughout the world. About a dozen companies worldwide are currently evaluating stem cell therapies in late stage clinical trials. Companies discussed in this report include those which have registered trials in Phase I through Phase III development. These include:
- Aastrom Biosciences
- Advanced Cell Technology
- Anterogen
- Antria
- apceth
- Arteriocyte
- Athersys
- Baxter
- BioCardia
- Bioheart
- BrainStorm Cell
- Capricor
- Celgene
- Cytomedix
- Cytori
- Gamida Cell
- GlaxoSmithKline
- ISCO
- Intrexon
- ISTO
- Medipost
- Mesoblast
- NeoStem
- Neuralstem
- Pharmicell
- Pluristem
- ReNeuron
- SanBio
- StemCells
- Stemedica Cell
- Stempeutics
- Targazyme
- TiGenix
- ViaCyte
Information for this report was gathered using both primary and secondary research. Primary research methods include telephone interviews and email correspondence with company representatives, researchers and physicians; secondary sources include comprehensive research of company reports and literature, government documents and databases, research journals and reports and general medical and business journals. Forecast dollar figures represent the estimated global market and are expressed in current dollars. Forecasts are provided through 2025. The size of each market segment refers to manufacturers' revenues.
Key Topics Covered:
ONE: EXECUTIVE SUMMARY
TWO: STEM CELLS: AN INTRODUCTION
THREE: REGULATORY LANDSCAPE AND RESEARCH POLICY
FOUR: DEVELOPMENT PROFILES AND ANALYSIS
FIVE: THERAPEUTIC APPLICATIONS: CURRENT AND POTENTIAL STEM CELL SEGMENTS
SIX: STEM CELL MARKET SUMMARY AND OUTLOOK
APPENDIX: INDUSTRY PARTICIPANTS
For more information visit http://www.researchandmarkets.com/research/d7qd97/stem_cell
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Share this article